Journal of clinical gastroenterology · 2026
Extraintestinal Cutaneous Manifestations in Inflammatory Bowel Disease Among Non-White Patients: A Retrospective Multicenter Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ailawadi Shaina, Sethi Sahil, Mahmood Abdullah, Harper Elleson, Perez Jaime, Cooper Gregory, Sinh Preetika, Nguyen Vu, Katz Jeffry, Cominelli Fabio, Regueiro Miguel, Mansoor Emad
Аннотация
BACKGROUND: The presence of extraintestinal manifestations with cutaneous diseases in patients with inflammatory bowel disease (IBD) can pose significant complications. Though the prevalence of IBD has been increasing in racial and ethnic minority groups, most literature has characterized several cutaneous manifestations (CM) of IBD in patients of white skin, with a lack of studies describing these complications in patients with other skin tones.
METHODS: Our study aimed to determine the rates of various CM of IBD in skin of color using a health care database to identify white and non-white patients with a diagnosis of IBD who were prescribed at least one IBD-specific medication or advanced therapy.
RESULTS: Of the total IBD patients, after propensity score matching there were 35,624 patients identified in both the white and non-white cohorts. Among non-white patients, there was a >2-fold odds of developing hidradenitis suppurativa and increased odds of vitiligo. Psoriasis, herpes zoster, and leukocytoclastic vasculitis exhibited a decreased association in non-white patients. There was no difference in erythema nodosum, pyoderma gangrenosum, oral aphthae, Sweet syndrome, and acquired epidermolysis bullosa.
CONCLUSION: With the rise of IBD in non-white populations, the representation of CM of IBD in this population is significantly limited, underrecognized, and thus undertreated. Our results reveal increased prevalence of several CM in the non-white IBD patient population. Recognition of CM in non-white patients with IBD can enhance quality of life and reduce morbidity among this population.
METHODS: Our study aimed to determine the rates of various CM of IBD in skin of color using a health care database to identify white and non-white patients with a diagnosis of IBD who were prescribed at least one IBD-specific medication or advanced therapy.
RESULTS: Of the total IBD patients, after propensity score matching there were 35,624 patients identified in both the white and non-white cohorts. Among non-white patients, there was a >2-fold odds of developing hidradenitis suppurativa and increased odds of vitiligo. Psoriasis, herpes zoster, and leukocytoclastic vasculitis exhibited a decreased association in non-white patients. There was no difference in erythema nodosum, pyoderma gangrenosum, oral aphthae, Sweet syndrome, and acquired epidermolysis bullosa.
CONCLUSION: With the rise of IBD in non-white populations, the representation of CM of IBD in this population is significantly limited, underrecognized, and thus undertreated. Our results reveal increased prevalence of several CM in the non-white IBD patient population. Recognition of CM in non-white patients with IBD can enhance quality of life and reduce morbidity among this population.